Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 10 of 10
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Additional file 1 of Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019–2022)
    (Figshare (United Kingdom), 2025-01-01)
    Mungun, Tuya
    ;
    Ulziibayar, Munkhchuluun
    ;
    Nguyen, Cattram D.
    ;
    Batsaikhan, Purevsuren
    ;
    Suuri, Bujinlkham
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Additional file 1 of Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019–2022)
    (Figshare (United Kingdom), 2025-01-01)
    Mungun, Tuya
    ;
    Ulziibayar, Munkhchuluun
    ;
    Nguyen, Cattram D.
    ;
    Batsaikhan, Purevsuren
    ;
    Suuri, Bujinlkham
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Additional file 1 of Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia
    (Figshare (United Kingdom), 2026-01-01)
    Amy Simkiss
    ;
    Munkhchuluun Ulziibayar
    ;
    Purevsuren Batsaikhan
    ;
    Bujinlkham Suuri
    ;
    Dashtseren Luvsantseren
    Supplementary Material 1: Supplementary Table 1. Describes demographic characteristics and risk factors with multiple categories in adults hospitalised with clinical community acquired pneumonia by severity status. The data in this table expands upon the binary categories used for these variables in Table 1.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019-2022)
    (2025-11)
    Mungun, Tuya
    ;
    Ulziibayar, Munkhchuluun
    ;
    Nguyen, Cattram D
    ;
    Batsaikhan, Purevsuren
    ;
    Suuri, Bujinlkham
    BACKGROUND: Streptococcus pneumoniae is an important cause of pneumonia in older adults, however, serotyping and indirect impact information from low and middle-income countries is lacking. Mongolia has a childhood 13-valent pneumococcal conjugate vaccine (PCV13) program, but no adult pneumococcal vaccination program. We describe pneumococcal carriage rates, disease and serotype distribution among adults hospitalised with pneumonia, and explore changes over the COVID-19 pandemic period. METHODS: Adults (≥ 18 years) hospitalised with clinical pneumonia were enrolled over 3 years (March 2019-February 2022) into a prospective pneumonia surveillance program. Nasopharyngeal swabs were tested to detect pneumococci using lytA qPCR and molecular serotyping by DNA microarray and metagenomics. Pneumococcal pneumonia was identified using serotype-specific urinary antigen detection and BinaxNOW® assays. Pneumococcal carriage and pneumonia prevalence were assessed over the COVID-19 period with log-binomial regression used to estimate prevalence and adjusted prevalence ratios (pre- versus early- and late-COVID-19 periods). RESULTS: Of 3,178 pneumonia cases, S. pneumoniae was identified in 12.1% (333/2,759) of swabs and 8.6% (253/2,925) of urine samples. PCV13 serotype carriage prevalence was 3.1% (82/2,663) and non-PCV13 serotype carriage prevalence 5.7% (152/2,663). In the late-COVID-19 period, pneumococcal carriage prevalence was reduced by 66% (aPR 0.34, 95%CI 0.25-0.46) and pneumococcal pneumonia by 82% (aPR 0.18, 95%CI 0.12-0.27) compared with the pre-COVID-19 transmission period. CONCLUSION: Despite paediatric vaccination with high coverage, we identified some residual PCV13 serotypes with predominance of non-PCV13 serotypes carried and causing disease in adults. Direct adult vaccination which targets these serotypes will potentially reduce disease in adults in Mongolia.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Additional file 1 of Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia
    (Figshare (United Kingdom), 2026-01-01)
    Amy Simkiss
    ;
    Munkhchuluun Ulziibayar
    ;
    Purevsuren Batsaikhan
    ;
    Bujinlkham Suuri
    ;
    Dashtseren Luvsantseren
    Supplementary Material 1: Supplementary Table 1. Describes demographic characteristics and risk factors with multiple categories in adults hospitalised with clinical community acquired pneumonia by severity status. The data in this table expands upon the binary categories used for these variables in Table 1.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    The Dynamics of the Prevalence of Acute Viral Hepatitis and the Strategies against Viral Hepatitis in Mongolia
    (2024) ;
    Badamjav, Tegshjargal
    ;
    ;
    Dashjamts, Gantogtokh
    ;
    BACKGROUND: Hepatocellular carcinoma (HCC) is the most common cancer in Mongolia. The relative importance of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in HCC etiology is known to vary greatly from one part of the world to another. Principally, 95% of HCC patients have chronic viral hepatitis, including 53% hepatitis B virus, 38.9% HCV, and 5.6% have HBV/HCV coinfection. Hepatitis D virus (HDV) infection is widely spread in our country, anti-HDV has been found in more than 25% of carriers who have HBsAg. MATERIALS AND METHODS: We analyzed data of patients who had been diagnosed with acute viral hepatitis in the Department of adult hepatitis, National Center for Communicable Diseases in Mongolia from 1952 to 2018. RESULTS: A total of 318,831 cases of acute viral hepatitis were registered in Mongolia between 1981 and 2019, which is 34.9 cases per 10,000 population. Of these, 265,931 cases of acute viral hepatitis A, or 28.6 per 10,000 populations, 48,855 cases of acute viral hepatitis B, or 5.5 cases per 10,000 populations, and 2,607 cases of acute viral hepatitis C, or 0.4 cases per 10,000 populations were recorded. CONCLUSION: The prevalence of viral hepatitis in our country was the highest in 1981-1991, but since 2012, the prevalence of infection has steadily decreased. In Mongolia, since 1960, multifaceted programs and activities to combat viral hepatitis have been successfully implemented at the national level. HOW TO CITE THIS ARTICLE: Badamnachin B, Badamjav T, Dondov G, et al. The Dynamics of the Prevalence of Acute Viral Hepatitis and the Strategies against Viral Hepatitis in Mongolia. Euroasian J Hepato-Gastroenterol 2024;14(1):65-69.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia hospitalisations in Mongolia: a time series analysis
    (2024-03)
    Fagerli, Kirsten
    ;
    Ulziibayar, Munkhchuluun
    ;
    Suuri, Bujinlkham
    ;
    Luvsantseren, Dashtseren
    ;
    Narangerel, Dorj
    BACKGROUND: Few studies have assessed the potential indirect effects of childhood pneumococcal conjugate vaccine (PCV) programs on the adult pneumonia burden in resource-limited settings. We evaluated the impact of childhood PCV13 immunisation on adult all-cause pneumonia following a phased program introduction from 2016. METHODS: We conducted a time-series analysis to assess changes in pneumonia hospitalisation incidence at four district hospitals in Mongolia. Adults (≥18 years) that met the clinical case definition for all-cause pneumonia were enrolled. A negative binomial mixed-effects model was used to assess the impact of PCV13 introduction on monthly counts of pneumonia admissions from January 2015-February 2022. We also performed a restricted analysis excluding the COVID-19 pandemic period. All models were stratified by age and assessed separately. Additional analyses assessed the robustness of our findings. FINDINGS: The average annual incidence of all-cause pneumonia hospitalisation was highest in adults 65+ years (62.81 per 10,000 population) and declined with decreasing age. After adjusting for the COVID-19 pandemic period, we found that rates of pneumonia hospitalisation remained largely unchanged over time. We did not observe a reduction in pneumonia hospitalisation in any age group. Results from restricted and sensitivity analyses were comparable to the primary results, finding limited evidence of a reduced pneumonia burden. INTERPRETATION: We did not find evidence of indirect protection against all-cause pneumonia in adults following childhood PCV13 introduction. Direct pneumococcal vaccination and other interventions should be considered to reduce burden of pneumonia among older adults. FUNDING: Pfizer clinical research collaboration agreement (contract number: WI236621).
    Scopus© Citations 5
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia
    (2026-01)
    Simkiss, Amy
    ;
    Ulziibayar, Munkhchuluun
    ;
    Batsaikhan, Purevsuren
    ;
    Suuri, Bujinlkham
    ;
    Luvsantseren, Dashtseren
    BACKGROUND: Limited research has focused on risk factors for community acquired pneumonia (CAP) in adults in low-middle income countries (LMICs). Mongolia has high rates of CAP hospitalisations with extreme winter temperatures and significant air pollution. We aimed to examine risk factors for severe CAP among hospitalised adults aged ≥ 18 years in Mongolia. METHODS: Adults hospitalised with clinical CAP were enrolled over three years (2019–2022) into a prospective CAP surveillance program in four district hospitals in the capital city, Ulaanbaatar. Participants had clinical information and risk factors collected using a case report form. Nasopharyngeal swabs were collected and tested for Streptococcus pneumoniae (the pneumococcus), influenza and respiratory syncytial virus, while collected urine was tested for the pneumococcus. From 2020 only patients with a negative SARS-CoV-2 test were enrolled in the study. Severe CAP was defined as clinical CAP with intensive care unit admission or ≥ 2 severity signs (confusion, hypotension, tachypnoea or hypoxaemia). Multivariable logistic regression was used to derive adjusted risk factor estimates. RESULTS: Overall, 3178 participants met the CAP study case definition and 10.1% had severe CAP. Pneumococcal carriage (aOR:2.67; 95% CI:1.88–3.79; p < 0.001), pneumococcal serotype-specific urine antigen detection positivity (aOR:1.69; 95% CI:1.11–2.57; p = 0.01), hospital admission within the last year (aOR:1.73; 95% CI:1.26–2.37; p = 0.001), underlying medical conditions (aOR:1.96; 95% CI:1.39–2.76; p < 0.001), cigarette smoking (aOR:1.53; 95% CI:1.08–2.16; p = 0.01) and alcohol intake (aOR:2.19; 95% CI:1.49–3.22; p < 0.001), were identified as risk factors for severe CAP on multivariable analysis. CONCLUSION: We identified key risk factors for severe CAP in hospitalised adults in urban Mongolia. If resources are limited, this data could be used to prioritise groups for vaccinations, alongside public health policies to decrease tobacco smoking and alcohol consumption.
    Scopus© Citations 1
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–2021
    (Centers for Disease Control and Prevention, 2024-02-23)
    Claire von Mollendorf
    ;
    Munkhchuluun Ulziibayar
    ;
    Cattram Duong Nguyen
    ;
    Purevsuren Batsaikhan
    ;
    Bujinlkham Suuri
    Starting in June 2016, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced into the routine immunization program of Mongolia by using a 2+1 dosing schedule, phased by district. We used prospective hospital surveillance to evaluate the vaccine's effect on pneumonia incidence rates among children 2-59 months of age over a 6-year period. Of 17,607 children with pneumonia, overall adjusted incidence rate ratios showed decreased primary endpoint pneumonia, very severe pneumonia, and probable pneumococcal pneumonia until June 2021. Results excluding and including the COVID-19 pandemic period were similar. Pneumonia declined in 3 districts that introduced PCV13 with catch-up campaigns but not in the 1 district that did not. After PCV13 introduction, vaccine-type pneumococcal carriage prevalence decreased by 44% and nonvaccine-type carriage increased by 49%. After PCV13 introduction in Mongolia, the incidence of more specific pneumonia endpoints declined in children 2-59 months of age; additional benefits were conferred by catch-up campaigns.
    Scopus© Citations 11
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Age-stratified prevalence of latent tuberculosis infection in Ulaanbaatar, Mongolia: a facility-based cross-sectional study
    (2026-09) ;
    Tumur, Enkhtsetseg
    ;
    Sharkhuu, Gundsuren
    ;
    Igarashi, Yuriko
    ;
    Ganbaatar, Gantungalag
    OBJECTIVES: Mongolia has a high tuberculosis (TB) burden. This study aimed to assess the age-specific latent TB infection (LTBI) prevalence in a healthy population in Mongolia by using interferon-gamma release assays. METHODS: This facility-based cross-sectional study was conducted from June 2024 to March 2025 in Ulaanbaatar. Eligible participants were asymptomatic, aged ≥10 years, had no previous TB treatment, and had no known contact with TB. LTBI was detected using the QuantiFERON-TB Gold Plus (QFT-Plus) assay. Sociodemographic data were collected using standardized questionnaires. RESULTS: The overall QFT-Plus positivity rate in 766 eligible participants (mean age: 38.2 years; 47.1% female) was 33.4%. Age-specific positivity increased from 7.9% (participants aged 10-19 years) to 46.1% (participants aged ≥60 years, P < 0.0001). Sex was not associated with positivity (P = 0.652), although the rate was slightly higher in women aged 40-59 years than in men. Multivariable analysis confirmed that age was a significant predictor of QFT-Plus positivity, reflecting TB prevalence. CONCLUSION: Ulaanbaatar's LTBI prevalence remains high, especially among older adults, suggesting a shift from recent transmission to remote infection reactivation. Although QFT-Plus positivity in young individuals remains high, our findings support the prioritization of targeted preventive strategies for older populations.